Current Therapeutic Innovations in the Treatment of Von Willebrand Disease
DOI:
10.29303/jbt.v25i4.10359Published:
2025-10-24Downloads
Abstract
Von Willebrand disease (vWD) is the most common hereditary bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (vWF), a key protein involved in both primary and secondary hemostasis. This study aims to review the current understanding of diagnosis, classification, and management strategies for vWD based on disease type and severity. A literature review approach was employed to analyze recent findings on the pathophysiology, diagnostic criteria, and therapeutic advances related to vWD. Accurate diagnosis remains crucial, as treatment must be tailored to the specific subtype and clinical severity. Current management focuses on increasing circulating levels of vWF and factor VIII through local hemostatic measures, antifibrinolytic agents such as tranexamic acid, desmopressin (DDAVP) for responsive patients, and vWF/factor VIII concentrates for severe cases or DDAVP contraindications. A multidisciplinary perioperative management plan is essential to minimize bleeding risks during surgical or invasive procedures. Despite advances in therapy, challenges persist in early detection and individualized treatment optimization. Comprehensive evaluation, improved clinical awareness, and collaborative care among healthcare providers are vital to enhancing patient outcomes and quality of life.
Keywords:
Antifibrinolytic therapy Von willebrand disease Von willebrand factorReferences
Ansori, Manual U, Brämswig K, Ploner F, Martel A, Bauernhofer T, et al. VON WILLEBRAND DISEASE. Science (80- ) [Internet]. 2022;7(1):1–8. Available from:http://link.springer.com/10.1007/s00232-01497019%x%0Ahttp://dx.doi.org/10.1016/j.jmr.2008.11.017%0Ahttp://linkinghub.elsevier.com/retrieve/pii/S1090780708003674%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/1191
Beltran A, Jaramillo AP, Vallejo MP, Acosta L, Barberan Parraga GC, Guanín Cabrera CL, et al. Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review. Cureus. 2023;15(8).
Briane, A., Horvais, V., Sigaud, M., Trossaërt, M., Drillaud, N., Ternisien, C., Fouassier, M., & Babuty, A. (2024). Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report. EJHaem, 5(5), 964–970. https://doi.org/10.1002/jha2.984
Castaman G, Linari S. Diagnosis and treatment of von willebrand disease and rare bleeding disorders. J Clin Med. 2017;6(4):1–18.
Chandrakumaran, P., Hews-Girard, J., & Poon, M. C. (2023). Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. Haemophilia : the official journal of the World Federation of Hemophilia, 29(4), 1095–1103. https://doi.org/10.1111/hae.14801
Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et al. Ash isth nhf wfh 2021 guidelines on the management of von willebrand disease. Blood Adv. 2021;5(1):301–25.
Eghbali, A., Melikof, L., Taherahmadi, H., & Bagheri, B. (2016). Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. Haemophilia : the official journal of the World Federation of Hemophilia, 22(5), e423–e426. https://doi.org/10.1111/hae.13051
Fatimah S, Surur MA, A’tourrohman M, Rohmah A, Khumaera F. Koagulasi dan Komposisi Darah. Fisiol Hewan. 2019;20(May):1–12.
James P, Leebeek F, Casari C, Lillicrap D. Diagnosis and treatment of von Willebrand disease in 2024 and beyond. Haemophilia. 2024;30(S3):103–11.
Kaur V, Elghawy O, Deshpande S, Riley D. von Willebrand disease: A guide for the internist. Cleve Clin J Med. 2024;91(2):119–27.
Kulkarni, B. P., Ghargi, K., Shanmukhaiah, C., & Shetty, S. D. (2022). Rare Occurrence of Inhibitors in Von Willebrand Disease: A Case Report. Frontiers in medicine, 8, 807664. https://doi.org/10.3389/fmed.2021.807664
Laan, S., Del Castillo Alferez, J., Cannegieter, S., Fijnvandraat, K., Kruip, M., le Cessie, S., Bierings, R., Eikenboom, J., & van Moort, I. (2025). DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis. Blood, 145(16), 1814–1825. https://doi.org/10.1182/blood.2024026804
Laffan, M., Sathar, J. and Johnsen, J. M. (2020) ‘von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis’, Haemophilia, 26(S3), pp. 72–81. Available at: https://doi.org/10.1111/hae.14050
Lenting, P. J., Kizlik-Manson, C. and Casari, C. (2022) ‘Towards novel treatment options in von Willebrand disease’, Haemophilia. Wiley, 28(4), pp. 593–600. Available at: https://doi.org/10.1111/hae.14518
Liang, Q., & Li, R. (2024). Recent advances in the diagnosis of von Willebrand disease. Laboratory Medicine and Diagnostics, https://doi.org/10.1016/j.lmd.2024.100020
Merz LE, AbdelHameid D, Kanaan DM, Farah S, Manzo P, Connell NT. Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease. Blood Adv [Internet]. 2024;8(9):2244–7. Available from: https://doi.org/10.1182/bloodadvances.2023012348
Michael Soucie J, Miller CH, Byams VR, Payne AB, Abe K, Sidonio RF, et al. Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia. 2021;27(3):445–53.
O'Donnell, J. S., & Lavin, M. (2019). Perioperative management of patients with von Willebrand disease. Hematology. American Society of Hematology. Education Program, 2019(1), 604–609. https://doi.org/10.1182/hematology.2019000065
Pagliari, M. T., Budde, U., Baronciani, L., Eshghi, P., Ahmadinejad, M., Badiee, Z., Baghaipour, M.-R., Benítez Hidalgo, O., Biguzzi, E., Bodó, I., Castaman, G., Goudemand, J., Karimi, M., Keikhaei, B., Lassila, R., Leebeek, F. W. G., Lopez Fernandez, M. F., Marino, R., Oldenburg, J., Peake, I., Santoro, C., Schneppenheim, R., Tiede, A., Toogeh, G., Tosetto, A., Trossaert, M., Yadegari, H., Zetterberg, E. M. K., Mannucci, P. M., Federici, A. B., Eikenboom, J., & Peyvandi, F. (2023) ‘von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS’, Journal of Thrombosis and Haemostasis. Available at: https://doi.org/10.1016/j.jtha.2023.01.001
Ragni, M. V., Rothenberger, S. D., Feldman, R., Nance, D., Leavitt, A. D., Malec, L., Kulkarni, R., Sidonio, R. Jr., Kraut, E., Lasky, J., Pruthi, R., Angelini, D., Philipp, C., Hwang, N., Wheeler, A. P., Seaman, C., Machin, N., Xavier, F., Meyer, M., Bellissimo, D., Humphreys, G., Smith, K. J., Merricks, E. P., Nichols, T. C., Ivanco, D., Vehec, D., Koerbel, G., & Althouse, A. D. (2023). Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): A phase 3, open-label, randomised, crossover trial. The Lancet Haematology, 10(8), e612–e623. https://doi.org/10.1016/S2352-3026(23)00119-9
Sato M, Hamada H, Hasegawa O, Kawase-Koga Y, Chikazu D. Orthognathic Surgery in Patients With Von Willebrand’s Disease: A Report of Four Cases and Literature Review. Cureus. 2024;16(July 2013):1–10.
Seidizadeh, O., Cairo, A., Baronciani, L., Valenti, L., & Peyvandi, F. (2023). Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases. NPJ genomic medicine, 8(1), 31. https://doi.org/10.1038/s41525-023-00375-8
Sharma, R., & Haberichter, S. L. (2019). New advances in the diagnosis of von Willebrand disease. Hematology. American Society of Hematology. Education Program, 2019(1), 596–600. https://doi.org/10.1182/hematology.2019000064
Stonebraker, J. S., Iorio, A., Lavin, M., Rezende, S. M., Srivastava, A., Pierce, G. F., Coffin, D., Tootoonchian, E., & Makris, M. (2023). Reported prevalence of von Willebrand disease worldwide in relation to income classification. Haemophilia : the official journal of the World Federation of Hemophilia, 29(4), 975–986. https://doi.org/10.1111/hae.14810
Weyand AC, Flood VH. Von Willebrand Disease: Current Status of Diagnosis and Management. Hematol Oncol Clin North Am. 2021;35(6):1085–101
License
Copyright (c) 2025 Baiq Bunga Citra Pratiwi, Cantika Brilliant Senna, Mohammad Rizki
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
